PureTech Health plc (OTCMKTS:PTCHF – Get Free Report)’s stock price fell 0.7% during trading on Friday . The stock traded as low as $2.12 and last traded at $2.12. 10,100 shares traded hands during trading, a decline of 69% from the average session volume of 33,049 shares. The stock had previously closed at $2.13.
PureTech Health Stock Down 0.7 %
The stock’s fifty day simple moving average is $1.94 and its two-hundred day simple moving average is $2.27.
PureTech Health Company Profile
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.
Read More
- Five stocks we like better than PureTech Health
- Dividend Payout Ratio Calculator
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- What Do S&P 500 Stocks Tell Investors About the Market?
- Top-Performing Non-Leveraged ETFs This Year
- Insider Trading – What You Need to Know
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
